세계의 IV 드레싱 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

IV Dressing Market Size, Share & Trends Analysis Report By Type (Transparent, Translucent), By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,876,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,368,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,351,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

IV 드레싱 시장의 성장과 동향 :

Grand View Research의 최신 보고서에 따르면, 세계 IV 드레싱 시장 규모는 2030년까지 12억 1,000만 달러에 달할 것으로 예상됩니다.

2024년부터 2030년까지 연평균 5.50%의 성장률을 보일 것으로 예상되며, CLABSI 및 CRBSI와 같은 혈액 감염 사례 증가와 입원 환자 수 증가가 시장 수요를 촉진할 것으로 보입니다. 또한, 노인 인구 증가와 만성질환의 유병률 증가도 시장 성장의 요인으로 작용하고 있습니다. 예를 들어, 세계보건기구(WHO)에 따르면 2015년부터 2050년 사이에 노인 인구 비율은 12%에서 22%로 두 배로 증가할 것으로 예상되며, 노년은 만성질환 발병의 중요한 위험요인으로 작용하고 있습니다. 암을 포함한 다양한 만성질환 치료에서 정맥주사 요법의 인지도 향상과 채택이 시장 성장의 원동력이 될 것으로 예상됩니다. 다양한 기업들이 새로운 정맥주사 치료제를 출시하고 있습니다.

예를 들어, 2023년 1월 Glenmark Pharmaceuticals Ltd.는 인도에서 화학요법으로 인한 구토와 메스꺼움을 예방하는 정맥주사 감염 치료제 AKYNZEO IV를 출시했습니다. 인수 등 주요 기업들의 전략적인 노력이 시장 성장에 기여할 것으로 예상됩니다. 예를 들어, 2022년 9월 B. Braun Medical Inc.는 Starboard Medical의 카테터 고정용 제품을 인수했습니다. 이를 통해 환자 치료를 개선하고 정맥주사 드레싱을 포함한 정맥주사 치료 제품을 확대할 것으로 예상됩니다. 또한, 주요 기업들의 지리적 확장 활동은 시장 성장을 가속할 것으로 예상됩니다. 예를 들어, 스미스 네퓨(Smith Nephew)는 2022년 1월 북유럽에서 제품 공급을 확대하기 위해 새로운 상업적 거점을 개설했습니다.

IV 드레싱 시장 보고서 하이라이트

• 투명 제품 부문은 2023년에 가장 큰 시장 점유율을 차지했으며며, 2024년부터 2030년까지 가장 빠른 CAGR 5.71%로 성장할 전망입니다.
• 이는 클로르헥시딘글루콘산염이 함침된 젤 패치가 포함된 새로운 투명 필름 드레싱을 도입하여 카테터 사용 기간 동안 부위를 지속적으로 소독할 수 있도록 한 것입니다.
• 병원 최종 용도 부문은 높은 의료 투자, 입원 건수 증가, 감염 및 만성 질환 발생으로 인해 2023년 45.39%의 가장 큰 매출 점유율을 차지할 것으로 예상됩니다.
• 북미는 2023년 45.46%로 가장 큰 매출 점유율을 차지했습니다. 이는 의료 인프라가 발달하고, 노인 인구가 많으며, 정맥주사 요법에 대한 인식과 도입률이 증가하고 있기 때문입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 IV 드레싱 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• IV 드레싱 시장 분석 툴
  • Porter의 Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 IV드레싱 : 유형 추정·동향 분석

• IV 드레싱 시장 : 유형 변동 분석
  • 투명
  • 반투명

제5장 IV드레싱 : 최종 용도 추정·동향 분석

• IV 드레싱 시장 : 최종 용도 변동 분석

제6장 IV 드레싱 시장 : 지역 추정·동향 분석

• 세계의 지역 시장 현황
• 북미
  • 미국
  • 캐나다
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 호주
  • 태국
  • 한국
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
• 중동 및 아프리카
  • 사우디아라비아
  • 남아프리카공화국
  • 아랍에미리트(UAE)
  • 쿠웨이트

제7장 경쟁 구도

• 주요 시장 진출기업의 최근 동향과 영향 분석
• 기업/경쟁 분류
  • 혁신기업
• 벤더 구도
  • 3M
  • RICHARDSON HEALTHCARE, INC.
  • MEDLINE INDUSTRIES
  • SMITH &NEPHEW
  • CARDINAL HEALTH
  • CONVATEC GROUP PLC
  • PAUL HARTMANN AG
  • LOHMANN &RAUSCHER(L&R)
  • MCKESSON CORPORATION
  • MOLNLYCKE HEALTH CARE AB
  • DERMARITE INDUSTRIES, LLC
  • DEROYAL INDUSTRIES, INC.
  • BSN MEDICAL
  • DYNAREX CORPORATION.
  • KOMAL HEALTH CARE PVT. LTD.
  • SENTRY MEDICAL
  • SHANDONG DERMCOSY MEDICAL CO.,LTD.

LSH

영문 목차

영문목차

IV Dressing Market Growth & Trends:

The global IV dressing market size is anticipated to reach USD 1.21 billion by 2030, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 5.50% from 2024 to 2030. Increasing cases of blood infections, such as CLABSI and CRBSI, and a rising number of hospital admissions are likely to boost market demand. Also, the rising geriatric population and increasing prevalence of chronic disorders are factors contributing to market growth. For instance, according to the WHO, between 2015 and 2050, the proportion of geriatric population is expected to double from 12% to 22%, making old age a significant risk factor for developing chronic disorders. A rise in awareness and adoption of IV therapy for treating various chronic diseases including cancer is anticipated to drive market growth. Various players are launching novel IV therapies.

For instance, in January 2023, Glenmark Pharmaceuticals Ltd. launched the IV infection formulation AKYNZEO IV in India to prevent chemotherapy-induced vomiting and nausea. Strategic initiatives undertaken by top players, such as acquisitions, are expected to contribute to market growth. For instance, in September 2022, B. Braun Medical Inc. acquired catheter securement products from Starboard Medical. This initiative was anticipated to improve patient care and extend the company's IV therapy offering including IV dressing. Furthermore, geographical expansion activities by key players are projected to boost market growth. For instance, in January 2022, Smith+Nephew inaugurated a new commercial hub to increase the company's product offerings in the Nordic region.

IV Dressing Market Report Highlights:

• The transparent product segment accounted for the largest market share in 2023 and is expected to grow at the fastest CAGR of 5.71% from 2024 to 2030
• This is owing to the introduction of a novel transparent film dressing with a chlorhexidine gluconate-impregnated gelpatch to offer ongoing disinfection of the site throughout the duration of the catheter
• The hospitals end-use segment held the largest revenue share of 45.39% in 2023 owing to the high healthcare investments, a rise in the number of hospitalizations, and incidences of infectious & chronic diseases
• North America captured the largest revenue share of 45.46% in 2023. This is owing to the well-developed healthcare infrastructure, high geriatric population, and rise in the awareness & adoption of IV therapies

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. End Use
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1.1. Commodity flow analysis (Model 1)
  • 1.6.1.2. Approach 1: Commodity flow approach
  • 1.6.1.3. Volume price analysis (Model 2)
  • 1.6.1.4. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. I.V. Dressing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing cases of blood infections such as CLABSI and CRBSI
    • 3.2.1.2. Increasing hospital admission
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Complications associated with I.V. dressing
• 3.3. I.V. Dressing Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. I.V. Dressing: Type Estimates & Trend Analysis

• 4.1. I.V. Dressing Market: Type Movement Analysis
  • 4.1.1. Transparent
    • 4.1.1.1. Transparent market estimates and forecast, 2018 - 2030
  • 4.1.2. Translucent
    • 4.1.2.1. Translucent market estimates and forecast, 2018 - 2030

Chapter 5. I.V. Dressing: End-use Estimates & Trend Analysis

• 5.1. I.V. Dressing Market: End-use Movement Analysis
  • 5.1.1. Hospitals
    • 5.1.1.1. Hospitals market estimates and forecast 2018 to 2030, (USD million)
  • 5.1.2. Clinics
    • 5.1.2.1. Clinics Institutes market estimates and forecast 2018 to 2030, (USD Million)
  • 5.1.3. Others
    • 5.1.3.1. Others market estimates and forecast 2018 to 2030, (USD million)

Chapter 6. I.V. Dressing Market: Regional Estimates & Trend Analysis

• 6.1. Global Regional Market Snapshot
• 6.2. North America
  • 6.2.1. North America Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.2.2. U.S.
    • 6.2.2.1. Key Country Dynamics
    • 6.2.2.2. Target Disease Prevalence
    • 6.2.2.3. Competitive Scenario
    • 6.2.2.4. U.S. Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.2.3. Canada
    • 6.2.3.1. Key Country Dynamics
    • 6.2.3.2. Target Disease Prevalence
    • 6.2.3.3. Competitive Scenario
    • 6.2.3.4. Canada Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
• 6.3. Europe
  • 6.3.1. Europe Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.3.2. UK
    • 6.3.2.1. Key Country Dynamics
    • 6.3.2.2. Target Disease Prevalence
    • 6.3.2.3. Competitive Scenario
    • 6.3.2.4. UK Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.3.3. Germany
    • 6.3.3.1. Key Country Dynamics
    • 6.3.3.2. Target Disease Prevalence
    • 6.3.3.3. Competitive Scenario
    • 6.3.3.4. Germany Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.3.4. France
    • 6.3.4.1. Key Country Dynamics
    • 6.3.4.2. Target Disease Prevalence
    • 6.3.4.3. Competitive Scenario
    • 6.3.4.4. France Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.3.5. Italy
    • 6.3.5.1. Key Country Dynamics
    • 6.3.5.2. Target Disease Prevalence
    • 6.3.5.3. Competitive Scenario
    • 6.3.5.4. Italy Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.3.6. Spain
    • 6.3.6.1. Key Country Dynamics
    • 6.3.6.2. Target Disease Prevalence
    • 6.3.6.3. Competitive Scenario
    • 6.3.6.4. Spain Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.3.7. Denmark
    • 6.3.7.1. Key Country Dynamics
    • 6.3.7.2. Target Disease Prevalence
    • 6.3.7.3. Competitive Scenario
    • 6.3.7.4. Denmark Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.3.8. Sweden
    • 6.3.8.1. Key Country Dynamics
    • 6.3.8.2. Target Disease Prevalence
    • 6.3.8.3. Competitive Scenario
    • 6.3.8.4. Sweden Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.3.9. Norway
    • 6.3.9.1. Key Country Dynamics
    • 6.3.9.2. Target Disease Prevalence
    • 6.3.9.3. Competitive Scenario
    • 6.3.9.4. Norway Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
• 6.4. Asia Pacific
  • 6.4.1. Asia Pacific Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.4.2. China
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Target Disease Prevalence
    • 6.4.2.3. Competitive Scenario
    • 6.4.2.4. China Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.4.3. Japan
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Target Disease Prevalence
    • 6.4.3.3. Competitive Scenario
    • 6.4.3.4. Japan Market estimates and forecast, 2018 - 2030 (Volume, Thousand)
  • 6.4.4. India
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Target Disease Prevalence
    • 6.4.4.3. Competitive Scenario
    • 6.4.4.4. India Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.4.5. Australia
    • 6.4.5.1. Key Country Dynamics
    • 6.4.5.2. Target Disease Prevalence
    • 6.4.5.3. Competitive Scenario
    • 6.4.5.4. Australia Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.4.6. Thailand
    • 6.4.6.1. Key Country Dynamics
    • 6.4.6.2. Target Disease Prevalence
    • 6.4.6.3. Competitive Scenario
    • 6.4.6.4. Thailand Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.4.7. South Korea
    • 6.4.7.1. Key Country Dynamics
    • 6.4.7.2. Target Disease Prevalence
    • 6.4.7.3. Competitive Scenario
    • 6.4.7.4. South Korea Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
• 6.5. Latin America
  • 6.5.1. Latin America Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.5.2. Brazil
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Target Disease Prevalence
    • 6.5.2.3. Competitive Scenario
    • 6.5.2.4. Brazil Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.5.3. Mexico
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Target Disease Prevalence
    • 6.5.3.3. Competitive Scenario
    • 6.5.3.4. Mexico Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.5.4. Argentina
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Target Disease Prevalence
    • 6.5.4.3. Competitive Scenario
    • 6.5.4.4. Argentina Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
• 6.6. MEA
  • 6.6.1. MEA Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.6.2. Saudi Arabia
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Target Disease Prevalence
    • 6.6.2.3. Competitive Scenario
    • 6.6.2.4. Saudi Arabia Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.6.3. South Africa
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Target Disease Prevalence
    • 6.6.3.3. Competitive Scenario
    • 6.6.3.4. South Africa Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.6.4. UAE
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Target Disease Prevalence
    • 6.6.4.3. Competitive Scenario
    • 6.6.4.4. UAE Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 6.6.5. Kuwait
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Target Disease Prevalence
    • 6.6.5.3. Competitive Scenario
    • 6.6.5.4. Kuwait Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
  • 7.2.1. Innovators
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2022
  • 7.3.4. 3M
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. RICHARDSON HEALTHCARE, INC.
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. MEDLINE INDUSTRIES
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. SMITH & NEPHEW
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. CARDINAL HEALTH
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. CONVATEC GROUP PLC
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. PAUL HARTMANN AG
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. LOHMANN & RAUSCHER (L&R)
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. MCKESSON CORPORATION
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. MOLNLYCKE HEALTH CARE AB
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Product benchmarking
    • 7.3.13.4. Strategic initiatives
  • 7.3.14. DERMARITE INDUSTRIES, LLC
    • 7.3.14.1. Company overview
    • 7.3.14.2. Financial performance
    • 7.3.14.3. Product benchmarking
    • 7.3.14.4. Strategic initiatives
  • 7.3.15. DEROYAL INDUSTRIES, INC.
    • 7.3.15.1. Company overview
    • 7.3.15.2. Financial performance
    • 7.3.15.3. Product benchmarking
    • 7.3.15.4. Strategic initiatives
  • 7.3.16. BSN MEDICAL
    • 7.3.16.1. Company overview
    • 7.3.16.2. Financial performance
    • 7.3.16.3. Product benchmarking
    • 7.3.16.4. Strategic initiatives
  • 7.3.17. DYNAREX CORPORATION.
    • 7.3.17.1. Company overview
    • 7.3.17.2. Financial performance
    • 7.3.17.3. Product benchmarking
    • 7.3.17.4. Strategic initiatives
  • 7.3.18. KOMAL HEALTH CARE PVT. LTD.
    • 7.3.18.1. Company overview
    • 7.3.18.2. Financial performance
    • 7.3.18.3. Product benchmarking
    • 7.3.18.4. Strategic initiatives
  • 7.3.19. SENTRY MEDICAL
    • 7.3.19.1. Company overview
    • 7.3.19.2. Financial performance
    • 7.3.19.3. Product benchmarking
    • 7.3.19.4. Strategic initiatives
  • 7.3.20. SHANDONG DERMCOSY MEDICAL CO.,LTD.
    • 7.3.20.1. Company overview
    • 7.3.20.2. Financial performance
    • 7.3.20.3. Product benchmarking
    • 7.3.20.4. Strategic initiatives

관련자료